Skip to main content
U.S. flag

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Find more clinical trials

Lucidity in Severe End-Stage Dementia

Start: June 2, 2022
End: May 2026
Enrollment: 520

What Is This Study About?

This study aims to establish methods for measuring episodes of lucidity, or episodes of clarity, in people with severe, end-stage dementia. The study is divided into two phases. In Phase 1, a family member, friend, or caregiver will record symptoms of the person with dementia in a diary, and researchers will measure brain activity through video electroencephalogram monitoring (video brain recording). Researchers will analyze how frequently the symptom diary entries indicate potential moments of lucidity and note any participant experiences of distress or discomfort from using the diary and video brain recording device. Phase 2 of the study aims to expand the study population, improve study methods, and create a definition and measurement scale for lucidity to inform future research.

Do I Qualify To Participate in This Study?

Minimum Age: 18 Years

Maximum Age: N/A

Must have:

  • Study participants will include:
    • Adults with severe dementia based on neurological testing
    • Hospice workers, geriatric and palliative care physicians, and other health care providers
    • Family, friends, and caregivers of a person with severe dementia
  • Participants with severe dementia will need to meet the following criteria:
    • Currently admitted or accepted for hospice care
    • No longer being provided with nutrition or fluids
    • Dry or almost dry disposable underwear in any 24-hour period

Must NOT have:

  • Mild, moderate, or moderately severe dementia, based on neurological testing
  • Cognitive or functional impairment due to a diagnosis other than dementia

If I Qualify, Who Do I Contact?

Contact study personnel listed either under the general study contact or the location nearest you.

 
Study Contact
Sam Parnia, MD, PhD
Anelly Gonzales

Need Help?

Contact NIA’s Alzheimer’s and related Dementias Education and Referral (ADEAR) Center at 800-438-4380 or email ADEAR.

Where Is This Study Located?

New York
NYU Langone Health
New York, NY 10016
Recruiting
Sam Parnia, MD, PhD

Who Sponsors This Study?

Lead: NYU Langone Health

Collaborator Sponsor

  • National Institute on Aging (NIA)

Source: ClinicalTrials.gov ID: NCT05234866

 

alzheimers.gov

An official website of the U.S. government, managed by the National Institute on Aging at the National Institutes of Health